GVHD Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
View More
Xue-Zhong Yu, MD, MS, MBA, discusses Sirtuin-1 as a possible therapeutic target for the control of GVHD.
View More
Oncologists may be able to reduce GVHD preventative measures for pediatric patients with acute leukemia post-HSCT.
View More
Stay in the know.
OncNet Newsletter